These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26768437)

  • 1. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
    Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
    Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
    Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
    Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
    Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
    Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
    Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
    Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
    Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
    Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
    Vig S; Seibert L; Green MR
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
    Wang XF; Feng Y; Chen Y; Gao BL; Han BH
    Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
    Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
    Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
    Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
    Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.
    Chow R; Valdez C; Chow N; Zhang D; Im J; Sodhi E; Lock M
    Support Care Cancer; 2020 May; 28(5):2095-2103. PubMed ID: 31916006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
    Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
    Fonte C; Fatigoni S; Roila F
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.